UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Vanda Pharmaceuticals Following FDA Decision

In a report published Tuesday, Jefferies analyst Oren G. Livnat reiterated a Buy rating on Vanda Pharmaceuticals VNDA, and raised the price target from $11.00 to $13.00. In the report, Jefferies noted, “FDA accepted the Tasimelteon NDA, granted priority review (8-month review, Jan 31, '14 action date), and set a tentative Advisory Committee meeting for Nov 14, '13. This signals to us that FDA 1) views ‘Non24' as a serious unmet need, 2) does not view this as another ‘insomnia' treatment, and 3) is receptive to the tasimelteon package. The AdCom panelist composition will be vital. Raise to $13 on further de-risking.” Vanda Pharmaceuticals closed on Monday at $8.05.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsJefferiesOren G. Livnat
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!